A new meta-analysis examines ADHD medication use during pregnancy, finding reassuring results for most outcomes while identifying a possible small increase in cardiovascular malformations with methylphenidate.
Melatonin is widely used as a sleep aid, but what do we know about its safety during pregnancy? Explore the evidence, potential risks, and treatment options.
A small phase 2a trial of GH001, an investigational psychedelic compound, found a rapid reduction in postpartum depression symptoms. Larger studies are needed to assess safety and durability.
Parents of infants in the NICU face high rates of depression, anxiety, stress, and trauma. Are we doing enough to identify their needs—and provide meaningful mental health support?
In this North American cross-sectional study, higher exposure to early life adversities was associated with a higher lifetime prevalence of physician-diagnosed PCOS/PMOS. The findings add to growing evidence that childhood adversities may have lasting effects on reproductive health.
Women with PMOS have significantly higher rates of depression and anxiety. Routine screening and integrated care are essential for improving psychiatric and reproductive outcomes.
Folic Acid Awareness Week (Sept 13-19, 2026) focuses on the importance of daily folic acid supplements for women to prevent birth defects, as diet alone is often insufficient.
For women who require treatment with quetiapine during pregnancy, the available reproductive safety data are generally reassuring. The largest body of evidence does not suggest a meaningful increase in major congenital malformations, while metabolic effects, particularly gestational diabetes, remain an important consideration.
If you or someone you know is in crisis, confidential support is available.
A new study examines pregnancy outcomes among women using stimulants or atomoxetine during pregnancy, finding modest increases in some complications with stimulant use while highlighting important limitations of observational data.
